Growth arrest-specific 5 lncRNA as a valuable biomarker of chemoresistance in osteosarcoma. Issue 3 (March 2022)

• Record Type: Journal Article
• Authors: Polvani, Simone; Martignano, Filippo; Scoccianti, Guido; Pasqui, Adriano; Palomba, Anna Rita; Conticello, Silvo; Galli, Andrea; Palchetti, Ilaria; Caporalini, Chiara; Antonuzzo, Lorenzo; Campanacci, Domenico Andrea; Pillozzi, Serena
• Is Part Of: Anti-cancer drugs. Volume 33:Issue 3(2022)
• Publication Date: 2022-03
• Subjects: biomarkers -- chemoresistance -- growth arrest-specific 5 -- long non coding RNA -- osteosarcoma; Antineoplastic agents -- Periodicals; Cancer -- Chemotherapy -- Periodicals; Antineoplastic Agents -- therapeutic use -- Periodicals; Drug Therapy -- Periodicals; 616.994061
• DOI: 10.1097/CAD.0000000000001263
• Languages: English
• ISSNs: 0959-4973

Abstract

Abstract : Osteosarcoma is the most common primary malignant bone tumour in children and teenagers, and it is characterised by drug resistance and high metastatic potential. Increasing studies have highlighted the critical roles of long noncoding RNAs (lncRNAs) as oncogenes or tumour suppressors as well as new biomarkers and therapeutic targets in osteosarcoma. The growth arrest-specific 5 (GAS5) lncRNA can function as a tumour suppressor in several cancers. The present study aimed to validate GAS5 and other chemoresistance-associated lncRNAs as biomarkers in a cohort of primary osteosarcoma samples, to obtain predictive information on resistance or sensitivity to treatment. The GAS5 and a panel of lncRNAs related to chemoresistance [SNGH1, FOXD2-AS1, deleted in lymphocytic leukemia (DLEU2) and LINC00963] were evaluated in a cohort of osteosarcoma patients enrolled at the Careggi University Hospital. Total RNA was extracted from formalin-fixed paraffin-embedded (FFPE) tissue sections and the expression levels of the lncRNAs were quantified by qPCR. A bioinformatic analysis on deposited RNA-seq data was performed to validate the qPCR results. Clustering analysis shows that GAS5 could be linked to the expression of isoforms 02 and 04 of the lncRNA DLEU2, whereas the DLEU2 isoform 08 is linked to the lncRNA LINC00963. We found that GAS5 is significantly increased in patients with a good prognosis and is expressed differently between chemosensitive and chemoresistant osteosarcoma patients. However, the results obtained are not concordant with the in-silico analysis performed on the TARGET osteosarcoma dataset. In the future, we would enlarge the case series, including different disease settings.